Predictive Value of GDF-15 and sST2 for Pulmonary Hypertension in Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
acute exacerbation of chronic obstructive pulmonary disease
growth differentiation factor-15
pulmonary hypertension
soluble suppression of tumorigenicity 2
Journal
International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
07
2023
accepted:
30
10
2023
medline:
14
11
2023
pubmed:
13
11
2023
entrez:
13
11
2023
Statut:
epublish
Résumé
To confirm whether growth differentiation factor-15 (GDF-15) and soluble suppression of tumorigenicity 2 (sST2) are indicators of pulmonary hypertension in acute exacerbation of chronic obstructive pulmonary disease (AECOPD-PH). All patients admitted to the hospital with AECOPD between July 2020 and October 2021 were enrolled. The patients were then categorized into AECOPD and AECOPD-PH groups according to PH probability, and the differences in GDF-15 and sST2 serum levels in the AECOPD and AECOPD-PH groups were compared. Correlation analysis was carried out to explore the association between GDF-15 and sST2 serum levels and the length of hospital stay of patients with AECOPD-PH. Receiver operating characteristic curve analysis was used to assess the clinical significance of GDF-15 and sST2 in predicting patients with AECOPD-PH. Included in this study were 126 patients with AECOPD, including 69 with AECOPD and 57 with AECOPD-PH. The serum levels of GDF-15 and sST2 in the AECOPD-PH group were significantly higher than those in the AECOPD group ( GDF-15 and sST2 levels may be useful in the prediction of AECOPD-PH.
Identifiants
pubmed: 37955023
doi: 10.2147/COPD.S429334
pii: 429334
pmc: PMC10637188
doi:
Substances chimiques
Biomarkers
0
Growth Differentiation Factor 15
0
GDF15 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2431-2438Informations de copyright
© 2023 Lv et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Int J Mol Sci. 2022 Nov 02;23(21):
pubmed: 36362162
Tuberc Respir Dis (Seoul). 2014 Dec;77(6):243-50
pubmed: 25580140
JAMA. 2019 Feb 26;321(8):786-797
pubmed: 30806700
Vnitr Lek. 2021 Summer;67(E-3):11-14
pubmed: 34171946
Front Cardiovasc Med. 2021 Nov 05;8:630818
pubmed: 34805295
Am J Respir Crit Care Med. 2021 May 15;203(10):1257-1265
pubmed: 33400890
Rev Port Cardiol. 2017 Feb;36(2):111-125
pubmed: 28117181
Int J Cardiol Heart Vasc. 2021 Oct 18;37:100887
pubmed: 34712771
Clin Chim Acta. 2020 Aug;507:75-87
pubmed: 32305537
J Clin Med. 2020 Aug 24;9(9):
pubmed: 32847145
Curr Opin Pulm Med. 2012 Mar;18(2):138-43
pubmed: 22189454
Chest. 2005 May;127(5):1531-6
pubmed: 15888824
Respiration. 1991;58(5-6):304-10
pubmed: 1792422
Lung India. 2011 Apr;28(2):105-9
pubmed: 21712919
Heart Lung Circ. 2020 Mar;29(3):337-344
pubmed: 31327702
J Clin Med. 2021 Dec 23;11(1):
pubmed: 35011794
Blood Cells Mol Dis. 2015 Aug;55(2):144-50
pubmed: 26142330
Arch Esp Urol. 2022 Mar;75(2):156-164
pubmed: 35332885
Int J Cardiol. 2013 Oct 3;168(3):3122
pubmed: 23632111
Heart. 2020 Mar;106(6):467-473
pubmed: 31492701
Pneumonol Alergol Pol. 2013;81(4):390-8
pubmed: 23744170
Mucosal Immunol. 2017 Nov;10(6):1400-1411
pubmed: 28145442
Resuscitation. 2020 Jul;152:165-169
pubmed: 32422242
Biomedicines. 2023 Jan 04;11(1):
pubmed: 36672632
Rheumatology (Oxford). 2022 Oct 6;61(10):3989-3996
pubmed: 35094054
Curr Med Sci. 2021 Jun;41(3):522-528
pubmed: 34169422
Respirology. 2021 Jun;26(6):532-551
pubmed: 33893708
Am J Respir Crit Care Med. 2021 Jan 1;203(1):24-36
pubmed: 33146552
Respir Res. 2018 Sep 3;19(1):169
pubmed: 30176857
Ann Intensive Care. 2019 Oct 17;9(1):119
pubmed: 31624933